MVA-HPV-IL2 Vaccine
MVA-HPV-IL2 Vaccine Uses, Dosage, Side Effects, Food Interaction and all others data.
| Trade Name | MVA-HPV-IL2 Vaccine |
| Generic | Tipapkinogene sovacivec |
| Tipapkinogene sovacivec Other Names | MVA-HPV-IL2 vaccine, Tipapkinogene sovacivec |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in cervical dysplasia/cancer, viral infection, and vulvar dysplasia and carcinoma.
How MVA-HPV-IL2 Vaccine works
TG 4001 is based on the modified vaccinia virus Ankara (MVA virus) carrying and expressing HPV16 E6 and E7 genes. The MVA vector is a highly attenuated strain of vaccinia virus that combines an extensive history of safety with the ability to stimulate a strong immune response to antigens. The TG 4001 therapeutic vaccine induces specific immunity by presentation of E6 and E7 antigens to T cells via major histocompatibility complex (MHC) class I and II inducing specific cellular and humoral responses. A second mechanism may be a non-specific activation of the immune system via the vaccinia virus and the interleukin 2 (IL2) adjuvant of the immune response. TG 4001 could have further applications beyond Cervical Intraepithelial Neoplasia (CIN) 2/3 as a single agent in low grade CIN (CIN1) or cervical cancers in combination with existing treatments. [Transgene press release]
Innovators Monograph
You find simplified version here MVA-HPV-IL2 Vaccine
